Comparative Pharmacology
Head-to-head clinical analysis: CYCLACILLIN versus NEO FRADIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLACILLIN versus NEO FRADIN.
CYCLACILLIN vs NEO-FRADIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. It also disrupts bacterial cell membrane integrity.
250-500 mg orally every 6 hours.
50-100 mg/kg/day orally in 3-4 divided doses. Maximum 3 g/day.
None Documented
None Documented
0.5–1 hour in adults with normal renal function; prolonged to 10–15 hours in anuria.
Clinical Note
moderateCyclacillin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cyclacillin."
Clinical Note
moderateCyclacillin + Mycophenolic acid
"The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cyclacillin resulting in a loss in efficacy."
Clinical Note
moderateCyclacillin + Plicamycin
"The serum concentration of Plicamycin can be decreased when it is combined with Cyclacillin."
Clinical Note
moderate2-3 hours in normal renal function; prolonged to 24-30 hours in anuria or severe renal impairment; no significant change in hepatic disease.
Primarily renal (90%) as unchanged drug via glomerular filtration and tubular secretion; negligible biliary/fecal elimination (<5%).
Renal: >90% unchanged drug via glomerular filtration, with small amount reabsorbed; biliary/fecal: <2%.
Category C
Category C
Antibiotic
Antibiotic
Cyclacillin + Valrubicin
"The serum concentration of Valrubicin can be decreased when it is combined with Cyclacillin."